Looking for health care's biggest gainers on the season? Boston Scientific (BSX 0.48%) is a name you should know. This device stock has surged by more than 95% in 2013, blowing away investors who have been troubled by the company's slumping sales and lagging cardiac rhythm management business in recent quarters. Boston Scientific showed progress in its second quarter earnings, but is this stock's momentum about to fall flat?
Boston Scientific posted flat sales in its third-quarter earnings release on Thursday, but that didn't stop investors from hammering this stock to the tune of a 6% decline. While the company's finances didn't disappoint on any major basis, the company's latest restructuring plan -- a deal that will see another 1,000 to 1,500 jobs cut as Boston Scientific looks to control costs -- has investors worried that this company's comeback could fall short.
Is Boston Scientific headed for a stock disaster, or will it keep up its momentum that has pleased Wall Street this year? Find out in the video below, where Fool contributor Dan Carroll tells you what you need to know about Boston Scientific's latest restructuring plan and how this cardiac device king can keep up with its top rivals in this hotly contested industry.
